申请人:Genentech, Inc.
公开号:US20140107099A1
公开(公告)日:2014-04-17
The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
7
and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
本发明提供了JAK激酶抑制剂Ia的公式,其对映体、对映异构体或其药学上可接受的盐,其中R1,R2,R7和Z在此定义,以及包括公式Ia化合物和药学上可接受的载体、佐剂或载体的制药组合物,以及用于治疗或减轻患者对JAK激酶活性抑制敏感的疾病或病情严重程度的方法。